Loading filters...
Publications per Year (894 total)
1
1990
2
1995
1
·
1
·
2
·
2
·
6
2000
2
·
3
·
5
·
7
·
11
2005
15
·
11
·
17
·
13
·
23
2010
17
·
34
·
48
·
37
·
54
2015
40
·
37
·
44
·
40
·
51
2020
61
·
56
·
38
·
62
·
97
2025
56
·
Loaded
Click to load
50 / 894 papers loaded(scroll for more)
202650 papers
LocoregionalAll Stages2026
Assessment of Survival Benefits Derived from Surgical Resection Subsequent to the Attainment of Complete Response upon Triple Therapy in Hepatocellular Carcinoma: A Multicenter Study.
Zhang X et al. Liver Cancer. 2026
LocoregionalAll Stages2026
Dynamic Risk Modelling of Hepatocellular Carcinoma.
Yu Z et al. Liver Int. 2026
LocoregionalAll Stages2026
Irreversible Electroporation versus Stereotactic Body Radiotherapy for Solitary Hepatocellular Carcinoma ≤ 5 cm: A Multicenter Retrospective Study.
Xu M et al. JHEP Rep. 2026
ImmunotherapyAdvanced (BCLC C)2026
Clinical impact of extrahepatic metastatic patterns in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.
Vo-Quang E et al. Eur J Cancer. 2026
LocoregionalAll Stages2026
TMEM87A suppresses ferroptosis and increases cancer immunotherapy resistance by maintaining the Golgi apparatus pH homeostasis.
Li J et al. Nat Cancer. 2026
ImmunotherapyAdvanced (BCLC C)2026
Second-Line TKI after First-Line Immunotherapy-based Treatment in Advanced HCC: Reconstructed IPD Meta-analysis.
Akkus E et al. JHEP Rep. 2026
ImmunotherapyAdvanced (BCLC C)2026
Alpha-Fetoprotein and Des-Gamma-Carboxy Prothrombin-Based Tumor Marker Score for First-Line Immunotherapy Selection in Hepatocellular Carcinoma.
Tanaka K et al. Liver Cancer. 2026
LocoregionalAdvanced (BCLC C)2026
Conversion Therapy Based on TACE/HAIC-Based Treatment to Improve the Therapeutic Effect of Initially Unresectable Hepatocellular Carcinoma.
Lin S et al. Liver Cancer. 2026
LocoregionalAll Stages2026
Targeting tumor-intrinsic STK40 induces immune vulnerability and drives T cell reinvigoration.
Zhu L et al. Cancer Cell. 2026
LocoregionalAll Stages2026
Outcomes of Y90-radioembolization as downstaging to liver transplantation in patients with hepatocellular carcinoma and tumoral portal vein thrombosis.
Sposito C et al. Hepatology. 2026
LocoregionalAll Stages2026
Loss of Hepatocyte PI3Kα Reduces Hepatocellular Carcinoma and Hepatocyte Proliferation in Association with Altered Lipid Metabolism.
Becattini B et al. JHEP Rep. 2026
ImmunotherapyAdvanced (BCLC C)2026
Lenvatinib Versus Bevacizumab in Combination With Anti-PD-1/PD-L1 Therapy for uHCC: A Meta-Analysis of East Asian Studies.
Wang X et al. Liver Int. 2026
GeneralEarly (BCLC 0-A)2026
Intratumoral Lactobacillus johnsonii Enhances Sensitivity to PD-1 Blockade by Inducing CD8+ T-cell Expansion in Hepatocellular Carcinoma.
Liu Q et al. Cancer Res. 2026
LocoregionalAdvanced (BCLC C)2026
Radiological Loco-Regional Treatments for Cholangiocarcinoma: A Systematic Review of the Literature.
Pallas D et al. Liver Int. 2026
ImmunotherapyAdvanced (BCLC C)2026
Clinical predictors of response to Atezolizumab-bevacizumab in Child-Pugh B patients with hepatocellular carcinoma.
Odent AV et al. JHEP Rep. 2026
ImmunotherapyAdvanced (BCLC C)2026
NRF2-COX2-PGE 2 axis drives immune cold tumors and predicts resistance to combination immunotherapy in hepatocellular carcinoma.
Yamamoto S et al. Hepatology. 2026
LocoregionalEarly (BCLC 0-A)2026
Integrating multiphase MRI surrogates to improve microvascular invasion detection and recurrence risk stratification in HCC.
Li F et al. JHEP Rep. 2026
LocoregionalAll Stages2026
MRI-Based Score to Predict Retreatment Response for Viable Hepatocellular Carcinomas After Transarterial Chemoembolization.
Wang W et al. Liver Int. 2026
LocoregionalAll Stages2026
Overall Survival Among Patients With Hepatocellular Carcinoma Treated With External Beam Radiation Therapy: Individual Patient Data Outcomes From a Multinational Cohort.
Moon AM et al. J Clin Oncol. 2026
LocoregionalEarly (BCLC 0-A)2026
Ultra-selective radiation segmentectomy for early-stage hepatocellular carcinoma.
Malone CD et al. JHEP Rep. 2026
ImmunotherapyAdvanced (BCLC C)2026
A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab Plus bevacizumab in hepatocellular caarcinoma.
Lombardi P et al. J Hepatol. 2026
LocoregionalEarly (BCLC 0-A)2026
Elevation of liver elasticity following radiofrequency ablation reflects neutrophil-mediated abscopal effect in liver cancer.
Lin K et al. JHEP Rep. 2026
ImmunotherapyEarly (BCLC 0-A)2026
Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: Long-term efficacy and biomarker exploration.
Lin YJ et al. J Hepatol. 2026
ImmunotherapyAdvanced (BCLC C)2026
Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.
Lee PC et al. Eur J Cancer. 2026
ImmunotherapyAll Stages2026
Impact of LEAP-012 and EMERALD-1 in the management of HCC.
Singal AG et al. JHEP Rep. 2026
LocoregionalAdvanced (BCLC C)2026
Yttrium-90 radioembolization is associated with a lower risk of liver transplant waitlist dropout than chemoembolization in hepatocellular carcinoma.
Kim NG et al. J Hepatol. 2026
ImmunotherapyAll Stages2026
Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma.
Yopp A et al. J Hepatol. 2026
ImmunotherapyEarly (BCLC 0-A)2026
IMAT-HCC model: Liver stiffness-enhanced integrated risk stratification for HCC recurrence after resection.
Serenari M et al. JHEP Rep. 2026
ImmunotherapyAll Stages2026
Phase II trial with nivolumab and sorafenib in HCC identified enrichment of immunosuppressive monocytes in patients with Child-Pugh B liver dysfunction.
Keenan BP et al. JHEP Rep. 2026
ImmunotherapyAdvanced (BCLC C)2026
Pembrolizumab and stereotactic body radiotherapy combined in advanced hepatocellular carcinoma post sorafenib - A phase II trial (PEMRAD).
O'Kane GM et al. JHEP Rep. 2026
TKIAdvanced (BCLC C)2026
Multicenter single-arm phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab.
Kim HD et al. J Hepatol. 2026
ImmunotherapyAdvanced (BCLC C)2026
Comparing of Efficacy and Safety Between Sintilimab Plus IBI305 and PD-1 Inhibitor Plus TKIs in Combination of TACE for uHCC.
Ya H et al. Liver Int. 2026
LocoregionalAll Stages2026
Hepatocellular Carcinoma in Egypt in the Post HCV Elimination Era: Changing Aetiology, Surveillance, and Management Pathways.
El-Kassas M et al. Liver Int. 2026
ImmunotherapyAdvanced (BCLC C)2026
Second-Line Practices in the Era of Immunotherapy in HCC: The CHIEF Cohort.
Decraecker M et al. JHEP Rep. 2026
ImmunotherapyAdvanced (BCLC C)2026
Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab.
Casadei-Gardini A et al. Eur J Cancer. 2026
ImmunotherapyAdvanced (BCLC C)2026
Multicenter study of bleeding and thromboembolic events with durvalumab tremelimumab vs. atezolizumab and bevacizumab in advanced HCC.
Ben Khaled N et al. JHEP Rep. 2026
ImmunotherapyAdvanced (BCLC C)2026
Outcomes of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC: An International Multicentre Study.
Kim JS et al. Liver Int. 2026
LocoregionalAdvanced (BCLC C)2026
Microbial metabolism dysfunction induced by transarterial chemoembolization aggravates postprocedural liver injury in HCC.
Li R et al. J Hepatol. 2026
ImmunotherapyAdvanced (BCLC C)2026
Plasma GPC3 reflects tumor GPC3 expression and predicts clinical outcomes in advanced HCC treated with atezolizumab + bevacizumab.
Shin DJ et al. JHEP Rep. 2026
LocoregionalEarly (BCLC 0-A)2026
Galectin-1 modulates glycolysis through a GM1-galactose-dependent pathway to promote hyperthermia resistance in HCC.
Nguyen T et al. Hepatology. 2026
ImmunotherapyAdvanced (BCLC C)2026
A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma.
El-Khoueiry AB et al. Hepatology. 2026
ImmunotherapyAdvanced (BCLC C)2026
Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real study.
Celsa C et al. JHEP Rep. 2026
LocoregionalAll Stages2026
Biologically explicable multimodal model predicting local tumor progression and tumor invasiveness of hepatocellular carcinoma.
Ding W et al. Hepatology. 2026
LocoregionalAdvanced (BCLC C)2026
Curative Treatment after Immunotherapy Leads to Excellent Outcomes in Patients with Hepatocellular Carcinoma.
Choi GH et al. Liver Cancer. 2026
GeneralEarly (BCLC 0-A)2026
Impact of gut microbiota on hepatocellular carcinoma: Pathogenesis, diagnosis, prognosis, and therapeutic prospective.
Chen Q et al. Eur J Cancer. 2026
ImmunotherapyAdvanced (BCLC C)2026
Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial.
Zhu HD et al. J Clin Oncol. 2026
LocoregionalAll Stages2026
CEUS-Based Microvascular Invasion Predictor in HCC: Improving Prognostic Stratification Following Thermal Ablation.
Chen K et al. Liver Int. 2026
LocoregionalEarly (BCLC 0-A)2026
High resolution spatial transcriptomics identifies insufficient radiofrequency ablation induces hepatocellular carcinoma progression via CEBPD / CXCL2 axis.
Lin K et al. Hepatology. 2026
ImmunotherapyAdvanced (BCLC C)2026
Long-term survival and cure fraction in patients with advanced hepatocellular carcinoma under immunotherapy in randomized controlled trials and real-world data.
Campani C et al. Clin Cancer Res. 2026
LocoregionalAdvanced (BCLC C)2026
Locoregional lactate dehydrogenase inhibition potentiates therapy and overcomes treatment resistance in hepatocellular carcinoma.
Boehmler DJ et al. Hepatology. 2026